OncoMatch/Clinical Trials/NCT04657861
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
Is NCT04657861 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies APRIL CAR-T cells for multiple myeloma in relapse.
Treatment: APRIL CAR-T cells — A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) positive expression
BCMA/TACI+ multiple myeloma (MM)
Required: TNFRSF13B positive expression
BCMA/TACI+ multiple myeloma (MM)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: CAR-T cell therapy
Exception: relapsed after BCMA CAR-T therapy allowed
Previously treated with any CAR-T cell product or other genetically modified T cell therapies
Lab requirements
Kidney function
creatinine ≤ 176.8 umol/L
Liver function
Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal
Cardiac function
Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%; Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past [excluded]
Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L; Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%; Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04657861 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy disqualifies patients from enrollment.
Does this trial require TNFRSF17?
Yes, TNFRSF17 positive expression is a required biomarker for enrollment.
Does this trial require TNFRSF13B?
Yes, TNFRSF13B positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages